Haleon plc Stock 12‑Month Price Target Cut to $11.07, Implies 11% Upside
Haleon plc's average stock price target was reduced from $11.15 to $11.07 by 16 analysts, with a range of $7.85 to $13.62. This implies an 11% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' among 18 analysts, with 11 Buys, 5 Holds, and 2 Sells.
How this was made

The 30-second read
Why it matters
The target reduction may lead to slight buying pressure if traders believe the stock is still undervalued, but the effect is expected to be muted.
Market read
A small analyst price‑target revision with limited immediate trading impact.
What to watch
Potential hidden risks in Haleon's pipeline or cost structure not reflected in the modest target change.
Background
Haleon plc is a consumer‑health company listed on NYSE under ticker HLN. The article reports a recent analyst consensus price‑target adjustment.
Ticker impact
Analyst price target for Haleon plc was lowered to $11.07, indicating a modest upside of ~11% from the current price.
modest upside as traders price in the 11% upside implied by the new target
Target revisions are a common catalyst; the change is small and the consensus remains a Buy, limiting immediate price move.
Market effects
Minor impact on consumer health & personal care sector as analysts adjust expectations.
Limited to US and European markets where Haleon trades.
Low; the revision does not affect broader market indices.
Counterpoint
Some investors may view the target cut as a buying opportunity given the still‑positive upside.
Key entities
- companyHaleon plc
Consumer‑health products maker, ticker HLN.



